Published in Blood on July 02, 2015
Present Yourself! By MHC Class I and MHC Class II Molecules. Trends Immunol (2016) 0.81
Current tools for predicting cancer-specific T cell immunity. Oncoimmunology (2016) 0.76
Expanding the peptidome for immunotherapy. Blood (2015) 0.75
Carfilzomib alters the HLA-presented peptidome of myeloma cells and impairs presentation of peptides with aromatic C-termini. Blood Cancer J (2016) 0.75
HLA class I-restricted MYD88 L265P-derived peptides as specific targets for lymphoma immunotherapy. Oncoimmunology (2016) 0.75
Carcinogenesis of renal cell carcinoma reflected in HLA ligands: A novel approach for synergistic peptide vaccination design. Oncoimmunology (2016) 0.75
HLA-A24 ligandome analysis of colon and lung cancer cells identifies a novel cancer-testis antigen and a neoantigen that elicits specific and strong CTL responses. Oncoimmunology (2017) 0.75
Tools to define the melanoma-associated immunopeptidome. Immunology (2017) 0.75
Immunologic approaches for the treatment of multiple myeloma. Cancer Treat Rev (2017) 0.75
Autologous bone marrow Th cells can support multiple myeloma cell proliferation in vitro and in xenografted mice. Leukemia (2017) 0.75
Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc (2009) 137.99
KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res (2000) 117.00
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med (2013) 18.08
Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med (2013) 17.53
Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med (2014) 16.83
T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature (1998) 12.70
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science (2015) 11.89
CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature (2003) 10.16
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med (2014) 10.10
Semi-supervised learning for peptide identification from shotgun proteomics datasets. Nat Methods (2007) 8.94
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet (2014) 8.63
Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science (2014) 6.88
Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med (2013) 6.01
Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol (2006) 5.72
Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med (2012) 5.44
Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer (2002) 5.30
Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J Clin Oncol (2013) 5.23
HLA-A2-peptide complexes: refolding and crystallization of molecules expressed in Escherichia coli and complexed with single antigenic peptides. Proc Natl Acad Sci U S A (1992) 5.02
T-helper-1-cell cytokines drive cancer into senescence. Nature (2013) 4.47
Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol (2012) 4.44
A vaccine targeting mutant IDH1 induces antitumour immunity. Nature (2014) 3.90
Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. J Clin Oncol (2014) 2.78
The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells. Blood (2010) 2.71
The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assays. Cancer Immunol Immunother (2007) 2.49
High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma. Nat Med (2014) 2.40
Long-term outcome results of the first tandem autotransplant trial for multiple myeloma. Br J Haematol (2006) 2.32
IMWG consensus on risk stratification in multiple myeloma. Leukemia (2013) 2.28
Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. Blood (2014) 2.25
Overexpression of transcripts originating from the MMSET locus characterizes all t(4;14)(p16;q32)-positive multiple myeloma patients. Blood (2005) 1.81
Mutated regions of nucleophosmin 1 elicit both CD4(+) and CD8(+) T-cell responses in patients with acute myeloid leukemia. Blood (2012) 1.65
Predicting population coverage of T-cell epitope-based diagnostics and vaccines. BMC Bioinformatics (2006) 1.55
Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up. J Clin Oncol (2011) 1.53
The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes. Cancer Res (2001) 1.50
Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma. Clin Cancer Res (2009) 1.48
RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses. Blood (2007) 1.47
Multiple myeloma. Lancet (2014) 1.46
Combination checkpoint blockade--taking melanoma immunotherapy to the next level. N Engl J Med (2013) 1.45
Distorted relation between mRNA copy number and corresponding major histocompatibility complex ligand density on the cell surface. Mol Cell Proteomics (2006) 1.26
Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma. Blood (2010) 1.23
MMSET deregulation affects cell cycle progression and adhesion regulons in t(4;14) myeloma plasma cells. Haematologica (2008) 1.20
NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses. Blood (2005) 1.19
Mouse urinary peptides provide a molecular basis for genotype discrimination by nasal sensory neurons. Nat Commun (2013) 1.18
A new era in anticancer peptide vaccines. Cancer (2010) 1.18
SYFPEITHI: database for searching and T-cell epitope prediction. Methods Mol Biol (2007) 1.18
High-dose RHAMM-R3 peptide vaccination for patients with acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma. Haematologica (2010) 1.17
Identification of a new HLA-A2-restricted T-cell epitope within HM1.24 as immunotherapy target for multiple myeloma. Exp Hematol (2006) 1.14
Orchestrating immune check-point blockade for cancer immunotherapy in combinations. Curr Opin Immunol (2014) 1.10
HLA ligand profiles of primary renal cell carcinoma maintained in metastases. Cancer Immunol Immunother (2009) 1.08
Mass spectrometry of human leukocyte antigen class I peptidomes reveals strong effects of protein abundance and turnover on antigen presentation. Mol Cell Proteomics (2015) 1.08
HLA ligandome analysis identifies the underlying specificities of spontaneous antileukemia immune responses in chronic lymphocytic leukemia (CLL). Proc Natl Acad Sci U S A (2014) 1.06
The potential role of epigenetic therapy in multiple myeloma. Br J Haematol (2009) 1.04
Minimal phenotype panels. A method for achieving maximum population coverage with a minimum of HLA antigens. Hum Immunol (1996) 1.02
Identification of novel myeloma-specific XBP1 peptides able to generate cytotoxic T lymphocytes: a potential therapeutic application in multiple myeloma. Leukemia (2011) 1.01
Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survival. Leukemia (2014) 1.00
Promiscuous survivin peptide induces robust CD4+ T-cell responses in the majority of vaccinated cancer patients. Int J Cancer (2011) 1.00
Mapping the HLA ligandome landscape of acute myeloid leukemia: a targeted approach toward peptide-based immunotherapy. Leukemia (2014) 1.00
Biochemical large-scale identification of MHC class I ligands. Methods Mol Biol (2013) 0.98
MMSET stimulates myeloma cell growth through microRNA-mediated modulation of c-MYC. Leukemia (2012) 0.96
Myeloma-specific multiple peptides able to generate cytotoxic T lymphocytes: a potential therapeutic application in multiple myeloma and other plasma cell disorders. Clin Cancer Res (2012) 0.96
Induction of HM1.24 peptide-specific cytotoxic T lymphocytes by using peripheral-blood stem-cell harvests in patients with multiple myeloma. Blood (2005) 0.92
Effector memory and central memory NY-ESO-1-specific re-directed T cells for treatment of multiple myeloma. Gene Ther (2012) 0.92
Pitfalls of vaccinations with WT1-, Proteinase3- and MUC1-derived peptides in combination with MontanideISA51 and CpG7909. Cancer Immunol Immunother (2010) 0.91
Potent costimulation of human CD8 T cells by anti-4-1BB and anti-CD28 on synthetic artificial antigen presenting cells. Cancer Immunol Immunother (2007) 0.91
Expression of putative targets of immunotherapy in acute myeloid leukemia and healthy tissues. Leukemia (2014) 0.90
Novel epitope evoking CD138 antigen-specific cytotoxic T lymphocytes targeting multiple myeloma and other plasma cell disorders. Br J Haematol (2011) 0.90
Generation of potent antitumor CTL from patients with multiple myeloma directed against HM1.24. Clin Cancer Res (2005) 0.88
Allogeneic hematopoietic stem cell transplantation for multiple myeloma: curative but not the standard of care. Curr Opin Oncol (2012) 0.87
Immunogenic peptide discovery in cancer genomes. Curr Opin Genet Dev (2015) 0.85
Long-term outcome after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with multiple myeloma. Am J Hematol (2013) 0.84
T cell-based targeted immunotherapies for patients with multiple myeloma. Int J Cancer (2014) 0.83
The translocation t(4;14) can be present only in minor subclones in multiple myeloma. Clin Cancer Res (2013) 0.82
Immunogenicity of dendritic cells pulsed with MAGE3, Survivin and B-cell maturation antigen mRNA for vaccination of multiple myeloma patients. Cancer Immunol Immunother (2013) 0.81
Plasma membrane proteomics identifies biomarkers associated with MMSET overexpression in T(4;14) multiple myeloma. Oncotarget (2013) 0.81
Peptide-based immunotherapy for multiple myeloma: current approaches. Vaccine (2010) 0.78
WT1 peptide vaccine as a paradigm for "cancer antigen-derived peptide"-based immunotherapy for malignancies: successful induction of anti-cancer effect by vaccination with a single kind of WT1 peptide. Anticancer Agents Med Chem (2009) 0.77
Immunotherapy for multiple myeloma. Expert Rev Hematol (2014) 0.76